Regeneron and Sanofi-Aventis announced that their experimental therapy aflibercept [1] missed a mid-stage goal for an ovarian cancer trial. The primary goal was a five percent response for established criteria at two dosages. At the higher dose, researchers tracked a 4.5 percent response and a 0.9 percent response at the lower dose.
Aflibercept is also being tested in late-stage trials for prostate, colorectal, pancreatic and non-small cell lung cancers. Both companies say they're now evaluating how to proceed developing the therapy.
- take a look at the announcement [2]
- read the AP story [3]
Related Articles:
Sanofi snags bigger stake, new pact with Regeneron [4]
Sanofi, Regeneron launch late-stage cancer studies [5]
Regeneron wins rich pact for VEGF trap [1]
Links:
[1] http://www.fiercebiotech.com/story/regeneron-wins-rich-pact-for-vegf-trap/2006-10-19
[2] http://www.fiercebiotech.com/press-releases/sanofi-aventis-and-regeneron-pharmaceuticals-cancer-drug-misses-study-goal
[3] http://www.businessweek.com/ap/financialnews/D90Q13680.htm
[4] http://www.fiercebiotech.com/story/sanofi-snags-bigger-stake-new-pact-regeneron/2007-11-29
[5] http://www.fiercebiotech.com/story/sanofi-regeneron-launch-late-stage-cancer-studies/2007-08-23